Migraine with Ophthalmic Features
This clinical presentation is most consistent with migraine, and you should continue ibuprofen at an adequate dose (400-600 mg) while considering escalation to combination therapy with a triptan if pain relief remains inadequate. 1
Diagnosis
The constellation of unilateral headache, painful eye globe with normal intraocular pressure, photophobia, and response to ibuprofen strongly suggests migraine with ophthalmic features rather than a primary ophthalmologic emergency. The normal intraocular pressure effectively rules out acute angle-closure glaucoma, which would be the primary vision-threatening concern in this presentation.
Key diagnostic features supporting migraine:
- Unilateral pain pattern
- Photophobia (a cardinal migraine-associated symptom)
- Response to NSAID therapy
- Normal intraocular pressure excluding glaucoma
- Periorbital/eye pain is common in migraine presentations 2
Acute Management Algorithm
Step 1: Optimize Current NSAID Therapy
Since the patient already responds to ibuprofen, first ensure adequate dosing:
- Ibuprofen 400-600 mg at symptom onset 1
- Maximum single dose: 800 mg
- Do not exceed 1200 mg/24 hours for OTC use 3
- Begin treatment as early as possible after headache onset for maximum efficacy 1
Step 2: If Inadequate Response to NSAID Alone
Add a triptan to the NSAID (combination therapy provides superior efficacy compared to monotherapy) 1:
- Sumatriptan + naproxen (or ibuprofen if naproxen contraindicated)
- Alternative triptans: rizatriptan, eletriptan, zolmitriptan, almotriptan
- Choice based on route preference (oral, nasal, subcutaneous) and cost 1
The 2025 American College of Physicians guideline demonstrates that combination therapy of a triptan with an NSAID results in:
- Higher likelihood of pain freedom at 2 hours (180 more events per 1000 people)
- Sustained pain relief up to 48 hours (180 more events per 1000 people)
- Lower rescue medication use (160 fewer events per 1000 people) 1
Step 3: If Combination Therapy Fails
Consider second-line agents for moderate-to-severe migraine 1:
- CGRP antagonists (gepants): rimegepant, ubrogepant, or zavegepant
- Ergot alkaloid: dihydroergotamine
- Ditan: lasmiditan (reserved for patients who fail all other treatments)
Critical Safety Considerations
Medication Overuse Headache
Monitor frequency of use carefully 1:
- NSAIDs: Risk increases with ≥15 days/month use
- Triptans: Risk increases with ≥10 days/month use
- If frequent episodic migraine develops, initiate preventive therapy rather than increasing acute medication frequency
NSAID Precautions
From FDA labeling 3:
- Monitor for GI bleeding risk (especially with chronic use)
- Contraindicated in aspirin-sensitive asthma
- Use caution with cardiovascular disease, renal impairment
- Avoid in pregnancy ≥30 weeks gestation
Absolute Contraindications
Do not use opioids or butalbital for acute episodic migraine treatment 1
When to Refer to Ophthalmology
While this presentation is consistent with migraine, urgent ophthalmology referral is warranted if:
- Vision loss develops
- Severe photophobia with anisocoria
- Restricted extraocular movements
- Corneal lesions on fluorescein examination
- Proptosis or hyphema 4
The normal intraocular pressure in this case is reassuring and argues against acute angle-closure glaucoma, which would require emergent intervention.
Preventive Therapy Consideration
If migraines occur frequently (≥4 per month) or acute treatment provides inadequate response, initiate preventive medications 1. This shifts the treatment paradigm from reactive to proactive management and reduces the risk of medication overuse headache.